Melanotan II: how it got to PCAC

Origin

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). The 2017 International Journal of Dermatology review by Habbema and colleagues described the molecule as one of two unapproved alpha-MSH analogues — alongside melanotan I — that began circulating in the unregulated tanning market in the 2000s PMID 28266027. Habbema et al. contrasted Melanotan II with afamelanotide, a related alpha-MSH analogue that has been formally developed, registered, and marketed under medical supervision for erythropoietic protoporphyria.

Research history

Indexed human-trial data on Melanotan II are limited. The published peer-reviewed record is dominated by case reports of adverse events. Habbema et al. catalogued cutaneous complications, melanocytic changes, eruptive nevi, and four reports of melanoma arising from existing moles during or after Melanotan II use; the authors observed that

Increasing numbers of case reports indicate that the unregulated use of both melanotan I and II is associated with cutaneous complications, particularly melanocytic changes.

A 2012 case report in Clinical Toxicology by Nelson and colleagues at the Toxikon Consortium described a patient who developed sympathomimetic toxicity, rhabdomyolysis with peak creatine kinase of 17,773 IU/L, and renal dysfunction after a 6 mg subcutaneous injection of Melanotan II — six times the unregulated “starting dose” available in online instructions PMID 23121206. Additional indexed case reports have described Melanotan II-associated priapism and renal infarction.

FDA enforcement history

Melanotan II has a documented FDA enforcement history that predates the current 503A bulk-substance review. On August 30, 2007, FDA issued a warning letter to Melanocorp, Inc., of Hendersonville, Tennessee, addressing the company’s online marketing of injectable Melanotan II as a tanning product and as a putative protectant against skin cancer and rosacea. The agency took the position that those marketing claims caused Melanotan II to meet the statutory definition of a drug under the Federal Food, Drug, and Cosmetic Act and a new drug for which no approved application existed. FDA followed the August 2007 letter with November 2007 correspondence to Melanocorp’s counsel reiterating that introduction of Melanotan II into interstate commerce, including export, would violate the FDCA. The warning-letter docket is available through FDA’s enforcement-letter index (FDA — Warning Letters).

National regulators in the United Kingdom, Australia, and several European jurisdictions issued parallel safety warnings in the 2000s and 2010s flagging unregulated melanotans as unapproved drugs of unknown purity.

Regulatory journey

Melanotan II has no FDA-approved drug application. Under the section 503A framework, a number of peptide bulk-drug nominations — including Melanotan II — were placed in Category 2 pending advisory-committee review, on the agency’s interim list of substances that “may present significant safety risks” (FDA Category 2 notice). The agency’s program page describes the bulks-list workflow, the three-category interim framework, and the PCAC review process (FDA — Bulk Drug Substances Used in Compounding).

FDA scheduled Melanotan II for the Pharmacy Compounding Advisory Committee meeting at the end of February 2027. PCAC’s role is to review the nomination, the agency’s safety analysis, and any public comment, and to recommend whether the substance should be added to the 503A bulks list.

What’s at stake

The published case-report record described above is the central element of the safety case the agency is expected to put before PCAC. A recommendation against inclusion would leave Melanotan II ineligible for compounding under section 503A and would consolidate FDA’s enforcement posture against bulk-substance use. A recommendation for inclusion — given the documented enforcement history and adverse-event signal — would be a notable departure from the agency’s existing posture. The February 2027 briefing materials, when released, are expected to be the most thorough consolidated FDA analysis of Melanotan II to date.